18F-Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management. Academic Article uri icon

Overview

abstract

  • [18/19F]-4, an anionic GCPII/PSMA inhibitor for image-guided intervention in prostate cancer, is described. [19F]-4 is radiolabeled with a radiochemical yield that is ≥27% and a molar activity of 190 ± 50 mCi/μmol in a <1 h, one-step, aqueous isotopic exchange reaction. [19F]-4 allows PSMA expression to be imaged by fluorescence (FL) and [18F]-PET. PC3-PIP (PSMA-positive, EC50 = 6.74 ± 1.33 nM) cancers are specifically delineated in mice that bear 3 million (18 mg) PC3-PIP and PC3 (control, PSMA-negative) cells. Colocalization of [18/19F]-4 PET, fluorescence, scintillated biodistribution, and PSMA expression are observed.

publication date

  • April 20, 2018

Research

keywords

  • Carbocyanines
  • Contrast Media
  • Electrons
  • Fluorine Radioisotopes
  • Positron-Emission Tomography
  • Prostatic Neoplasms

Identity

PubMed Central ID

  • PMC6263152

Scopus Document Identifier

  • 85046786143

Digital Object Identifier (DOI)

  • 10.1021/acs.jmedchem.8b00240

PubMed ID

  • 29676909

Additional Document Info

volume

  • 61

issue

  • 9